Table 2 Frequencies of predicted high-risk phenotypes within the studied cohort (GS, GSA, and OMNI data combined) and gene-related drug consumption statistics in European Nordic countries
Gene | Phenotype | % of individuals (phenotype, source) | % of individuals (gene total) | Number of drug active substances affected | DDDa/1000 inhabitants, (min–max)b | ||
|---|---|---|---|---|---|---|---|
GS | GSA | OMNI | |||||
CYP2C19 | Intermediate metabolizer | 23.6 | 23.2 | 24.0 | 63.7 | 10 | 17.62–66.83 |
Poor metabolizer | 2.44 | 2.16 | 2.34 | ||||
Rapid metabolizer | 31.2 | 30.7 | 31.2 | ||||
Ultrarapid metabolizer | 6.86 | 7.40 | 7.23 | ||||
CYP2C9 | Intermediate metabolizer | 25.8 | 26.1 | 25.1 | 28.4 | 2 | 7.08–16.26 |
Poor metabolizer | 2.40 | 2.49 | 2.32 | ||||
CYP2D6 | Intermediate metabolizer | 3.93 | 3.26 | 2.96 | 7.65 | 16 | 9.16–15.92 |
Poor metabolizer | 4.96 | 4.07 | 3.67 | ||||
Ultrarapid metabolizer | 2.36 | 0.27 | 0 | ||||
CYP3A5 | Intermediate metabolizer | 13.5 | 12.8 | 11.9 | 13.2 | 1 | 0–0.5 |
Normal metabolizer | 0.62 | 0.51 | 0.55 | ||||
CYP4F2 | Higher dose phenotype | 0.29 | 0.36 | 0.33 | 70.5 | 1 | 7.02–16.04 |
Increased CYP4F2 activity | 0.04 | 0.02 | 0.03 | ||||
Lower dose phenotype | 71.3 | 69.8 | 71.3 | ||||
DPYD | Intermediate metabolizer | 1.36 | 0.90 | 0.87 | 0.92 | 3 | 0 |
Poor metabolizer | 0 | 0.006 | 0 | ||||
IFNL3 | Unfavorable response | 58.5 | 56.7 | 56.7 | 56.8 | 3 | 0–0.23 |
SLCO1B1 | Decreased function | 34.0 | 34.9 | 35.2 | 40.1 | 1 | 6.13–62.9 |
Poor function | 4.38 | 5.24 | 5.47 | ||||
TPMT | Intermediate metabolizer | 5.54 | 6.37 | 6.33 | 6.40 | 3 | 0.32–1.41 |
Poor metabolizer | 0.21 | 0.07 | 0.08 | ||||
UGT1A1 | Intermediate metabolizer | 45.9 | 46.2 | 45.3 | 59.0 | 2 | 0–0.09 |
Poor metabolizer | 12.3 | 13.1 | 12.6 | ||||
VKORC1 | Decreased dose phenotype | 56.5 | 57.5 | 57.5 | 57.4 | 1 | 7.02–16.04 |
